Bold Moves

Deliver first-in-class science

Win the digital race in pharma

Subject to regulatory approvals, Pfizer aims to deliver six innovative vaccines by 2025

For over a decade, Pfizer has worked with focus and rigor to build the capabilities that have allowed us to quadruple the number of vaccine programs in the clinic, and most recently, to quickly mobilize to develop a COVID-19 vaccine candidate in collaboration with BioNTech SE to help combat the COVID-19 pandemic. In 2020, Pfizer initiated five new global Phase 3 trials across nine programs in active clinical development.

We have built a robust and exciting vaccines pipeline with the potential to launch six innovative vaccines by 2025."​​​​​​​

Kathrin U. Jansen

Senior Vice President and Head of Vaccine Clinical Research and Development


In 2020, Pfizer initiated five new Phase 3 trials across nine programs in active clinical development.

Candidates for the potential “six by 2025” are vaccines to help prevent COVID-19, pneumococcal disease in adults and pediatric populations, C. difficile, meningococcal disease, respiratory syncytial virus and Lyme disease.

"We are incredibly proud of the momentum we are building in the face of a uniquely challenging year,” said Nanette Cocero, President, Pfizer Vaccines. “What drives us the most are those millions of people across the globe who are depending on us to make ‘six by 2025’ a reality.”​​​​​​​

​​​​​​​The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at

 In just over a decade Pfizer has quadrupled our vaccine programs in the clinic.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories